Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma.

Suppr

超能文献

作者信息

van de Donk Niels W C J, Wittebol Shulamit, Minnema Monique C, Lokhorst Henk M

出版信息

Br J Haematol. 2010 Jan;148(2):335-7. doi: 10.1111/j.1365-2141.2009.07931.x.

DOI:10.1111/j.1365-2141.2009.07931.x

PMID:20085583

Abstract

摘要

相似文献

Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma.

Br J Haematol. 2010 Jan;148(2):335-7. doi: 10.1111/j.1365-2141.2009.07931.x.

Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients.

Br J Haematol. 2007 May;137(3):268-9. doi: 10.1111/j.1365-2141.2007.06538.x.

Treatment with lenalidomide (Revlimid®), cyclophosphamide (Endoxan®) and prednisone (REP) in relapsed/refractory multiple myeloma patients: results of a single centre retrospective study.

Acta Clin Belg. 2014 Apr;69(2):98-103. doi: 10.1179/0001551214Z.00000000030. Epub 2014 Mar 4.

Lenalidomide and its role in the management of multiple myeloma.

Expert Rev Anticancer Ther. 2008 Jun;8(6):865-74. doi: 10.1586/14737140.8.6.865.

DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.

J Clin Oncol. 2003 Jul 15;21(14):2732-9. doi: 10.1200/JCO.2003.01.055.

Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.

Br J Haematol. 2015 Jan;168(1):46-54. doi: 10.1111/bjh.13100. Epub 2014 Aug 22.

Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.

Eur J Cancer. 2011 Apr;47(6):814-8. doi: 10.1016/j.ejca.2010.12.026. Epub 2011 Feb 18.

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.

J Clin Oncol. 2007 Oct 1;25(28):4459-65. doi: 10.1200/JCO.2007.12.3463. Epub 2007 Sep 4.

Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma.

Br J Haematol. 2005 Jun;129(6):763-70. doi: 10.1111/j.1365-2141.2005.05521.x.

Treatment of multiple myeloma: 2009 update.

Prescrire Int. 2009 Dec;18(104):263-6.

引用本文的文献

Management of Relapsed-Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice.

Cancers (Basel). 2023 Apr 5;15(7):2160. doi: 10.3390/cancers15072160.

The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma.

Ann Hematol. 2020 Aug;99(8):1709-1725. doi: 10.1007/s00277-020-04023-4. Epub 2020 Apr 16.

Management of multiple myeloma in the relapsed/refractory patient.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):508-517. doi: 10.1182/asheducation-2017.1.508.

A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma.

Ther Adv Hematol. 2016 Dec;7(6):330-344. doi: 10.1177/2040620716667275. Epub 2016 Sep 13.

Treatment of relapsed and refractory multiple myeloma.

Haematologica. 2016 Apr;101(4):396-406. doi: 10.3324/haematol.2015.129189.

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.

Leukemia. 2016 May;30(5):1005-17. doi: 10.1038/leu.2015.356. Epub 2015 Dec 29.

Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.

Leukemia. 2015 Sep;29(9):1945-8. doi: 10.1038/leu.2015.54. Epub 2015 Feb 27.

Novel agents and new therapeutic approaches for treatment of multiple myeloma.

World J Methodol. 2014 Jun 26;4(2):73-90. doi: 10.5662/wjm.v4.i2.73.

Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma.

Am J Hematol. 2014 Aug;89(8):E116-20. doi: 10.1002/ajh.23733. Epub 2014 Apr 26.

Successful use of cyclophosphamide as an add-on therapy for multiple myeloma patients with acquired resistance to bortezomib or lenalidomide.

Case Rep Hematol. 2013;2013:651902. doi: 10.1155/2013/651902. Epub 2013 Mar 28.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验